Article
Multidisciplinary Sciences
Man Yang, Jiale Sun, Liqiong Liu, Xiangyi Kong, Dongcai Lin, Hong Zhou, Jidong Gao
Summary: This study aimed to explore the differences in clinicopathological indicators and survival outcomes between HER2-low and HER2-0 breast cancers. Retrospectively analyzing 501 invasive breast cancer patients, it was found that HER2-low breast cancer was significantly higher in HR positive breast cancers, and significant differences were observed in lymph node ratio, hormone receptor expression, Ki-67 expression, androgen receptor expression, and adjuvant chemotherapy between HER2-low BCs and HER2-0 BCs. No statistical differences were detected between the two groups for DFS and DDFS.
SCIENTIFIC REPORTS
(2023)
Article
Neurosciences
Alev Selek, Zehra Seda Unal Halbutogullari, Cigdem Inci Aydemir, Berrin Cetinarslan, Zeynep Canturk, Ilhan Tarkun, Gulay Erman, Cansu Subasi, Karaoz Erdal
Summary: This study investigates the potential of using an aromatase inhibitor as a substitute for testosterone in treating prolactinomas. The findings reveal that the aromatase inhibitor can inhibit cell proliferation and induce apoptosis in prolactinoma cells, as well as reduce prolactin and estrogen levels.
MOLECULAR NEUROBIOLOGY
(2023)
Article
Oncology
Guilherme Nader-Marta, Veronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Saranya Chumsri, Kathleen Pritchard, Michael Untch, Meritxell Bellet-Ezquerra, Daniela Dornelles Rosa, Alvaro Moreno-Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja
Summary: The sub-analysis of the ALTTO trial demonstrates that patients with small node-negative breast cancer treated with trastuzumab and concomitant chemotherapy have excellent long-term outcomes.
BRITISH JOURNAL OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Chih-Jung Chen, Ting-Hao Chen, Jason Lei, Ji-An Liang, Po-Sheng Yang, Chiun-Sheng Huang, Chia-Ming Hsieh, Ling-Ming Tseng, Liang-Chih Liu, Skye Hung-Chen Cheng, Kuan-Hui Shih
Summary: This study compared the biomarker expression and breast cancer subtyping results obtained by immunohistochemistry (IHC) and reverse transcriptase-polymerase chain reaction (RT-PCR). The results showed concordance between the two methods, and RT-PCR performed similarly to IHC in predicting 5-year survival.
BIOSCIENCE REPORTS
(2022)
Article
Oncology
Chewei Anderson Chang, Jayu Jen, Shaowen Jiang, Azin Sayad, Arvind Singh Mer, Kevin R. Brown, Allison M. L. Nixon, Avantika Dhabaria, Kwan Ho Tang, David Venet, Christos Sotiriou, Jiehui Deng, Kwok-Kin Wong, Sylvia Adams, Peter Meyn, Adriana Heguy, Jane A. Skok, Aristotelis Tsirigos, Beatrix Ueberheide, Jason Moffat, Abhyudai Singh, Benjamin Haibe-Kains, Alireza Khodadadi-Jamayran, Benjamin G. Neel
Summary: Resistance to targeted therapies in HER2-positive breast cancer is often attributed to the presence of drug-tolerant persisters (DTPs). This study reveals that HER2 TKI treatment leads to the emergence of DTPs with different transcriptomes, and these DTPs are originated from pre-DTP cells that cycle stochastically. The findings provide insights into the ontogeny of DTPs and potential vulnerabilities for therapeutic targeting.
Article
Biochemistry & Molecular Biology
Chung-Liang Li, Sin-Hua Moi, Huei-Shan Lin, Ming-Feng Hou, Fang-Ming Chen, Shen-Liang Shih, Jung-Yu Kan, Chieh-Ni Kao, Yi-Chia Wu, Li-Chun Kao, Ying-Hsuan Chen, Yi-Chen Lee, Chih-Po Chiang
Summary: This study identifies candidate gene sets that play critical roles in the resistance of endocrine therapy for hormone-receptor-positive breast cancer. These gene sets can differentiate different treatment response groups and are significantly correlated with survival outcomes. This has important clinical implications for the diagnosis, mechanism, and therapeutic strategy in the future.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Medicinal
Jingru Qiu, Qinghong Liu, Peixia Li, Qiaoyun Jiang, Weijia Chen, Donghai Li, Guiling Li, Gang Shan
Summary: This work presents a photocatalytic approach called ligand-directed photodegradation of interacting proteins (LDPIP) for efficient degradation of protein-protein heterodimers. LDPIP utilizes a photosensitizing protein ligand, appropriate light, and molecular oxygen to induce oxidative damage to both the ligand-binding protein and its interacting protein partner. As a showcase study, a photosensitizing HER2 ligand HER-PS-I was designed based on the FDA-approved HER2 inhibitor lapatinib to degrade HER2 and its difficult-to-target interacting protein partner HER3. HER-PS-I exhibited excellent anticancer activity in drug-resistant MDA-MB-453 cells and multicellular spheroids. The LDPIP approach holds promise for degrading undruggable or difficult-to-drug proteins.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Oncology
Mark M. Moasser
Summary: The pharmaceutical inactivation of driver oncogenes has revolutionized cancer treatment, but challenges remain for HER2-amplified cancers. The monotherapy activities associated with HER2-targeting therapies are not as effective as for other oncogene-driven cancers. Further research is needed to understand the mechanism of HER2 inactivation for treatment.
Article
Oncology
Ana Carla Castro-Guijarro, Angel Matias Sanchez, Marina Ines Flamini, Christoph F. A. Vogel
Summary: This study aims to identify biomarkers for predicting disease progression and therapy efficacy in HER2-positive breast cancer, as well as to overcome resistance. Combining anti-HER2 therapies shows potential in inhibiting cell adhesion and migration critical for cancer metastasis. Deregulated proteins in resistant cells may serve as potential biomarkers of therapy response and resistance. These findings are promising for personalized breast cancer management to maximize the safety and efficacy of anti-HER2 therapies.
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Article
Chemistry, Medicinal
Lilan Xin, Jian Min, Hebing Hu, Yuanyuan Li, Chuanqian Du, Baohua Xie, Yan Cheng, Xiaofei Deng, Xiangping Deng, Kang Shen, Jian Huang, Chun -Chi Chen, Rey-Ting Guo, Chune Dong, Hai -Bing Zhou
Summary: In this study, a novel class of dual-targeting selective estrogen receptor degraders (SERDs) based on a three-dimensional oxabicycloheptene sulfonamide (OBHSA) scaffold equipped with aromatase inhibitor (AI) activity were identified. These compounds showed excellent ERa degradation activity, ARO inhibitory activity, and antiproliferative activity against drug-resistant breast cancer cells.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Medical Laboratory Technology
Priyanila Magesh, Sanu Thankachan, Thejaswini Venkatesh, Padmanaban S. Suresh
Summary: The fibroblasts in the breast tumor microenvironment are crucial for tumor progression and metastasis, as they provide energy to adjacent cancer cells through metabolic reprogramming and secrete growth factors to promote tumor growth and dissemination. Identifying effective strategies to target the reprogrammed metabolism and communication between fibroblasts and cancer cells could lead to promising anti-cancer therapeutics.
CLINICA CHIMICA ACTA
(2021)
Article
Immunology
Xiaoxue Wu, Shuting Huang, Weiling He, Mei Song
Summary: HER2 is a therapeutic target in various types of cancer with HER2 overexpression or genomic alterations. Trastuzumab, a humanized monoclonal antibody targeting HER2, has improved the clinical outcomes of HER2-positive patients. However, resistance to trastuzumab poses a challenge, and this review explores the mechanisms of resistance and discusses potential strategies for improving patient outcomes through rational combinations.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Rashidra R. Walker, Jankiben R. Patel, Akash Gupta, A. Michael Davidson, Christopher C. Williams, Florastina Payton-Stewart, Stephen M. Boue, Matthew E. Burow, Rahul Khupse, Syreeta L. Tilghman
Summary: The combination treatment of glyceollins and lapatinib could reduce the proliferation of hormone-dependent letrozole-resistant breast cancer cells by inducing apoptosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Nina E. Weisser, Mario Sanches, Eric Escobar-Cabrera, Jason O'Toole, Elizabeth Whalen, Peter W. Y. Chan, Grant Wickman, Libin Abraham, Kate Choi, Bryant Harbourne, Antonios Samiotakis, Andrea Hernandez Rojas, Gesa Volkers, Jodi Wong, Claire E. Atkinson, Jason Baardsnes, Liam J. Worrall, Duncan Browman, Emma E. Smith, Priya Baichoo, Chi Wing Cheng, Joy Guedia, Sohyeong Kang, Abhishek Mukhopadhyay, Lisa Newhook, Anders Ohrn, Prajwal Raghunatha, Matteo Zago-Schmitt, Joseph D. Schrag, Joel Smith, Patricia Zwierzchowski, Joshua M. Scurll, Vincent Fung, Sonia Black, Natalie C. J. Strynadka, Michael R. Gold, Leonard G. Presta, Gordon Ng, Surjit Dixit
Summary: In this study, the authors engineered an anti-HER2 biparatopic antibody, zanidatamab, with multiple mechanisms of action, including induction of HER2 clustering to trigger complement-dependent cytotoxicity, signal inhibition, antibody-dependent cellular cytotoxicity, and phagocytosis. Zanidatamab showed superior in vivo antitumor activity compared to tras + pert in a HER2-expressing xenograft model.
NATURE COMMUNICATIONS
(2023)